Evaluation of PD-L1 as a Biomarker for Immunotherapy for Hepatocellular Carcinoma: Systematic Review and Meta-Analysis
Xueyin Zhou, Jiasheng Cao, Win Topatana, Tian‐Ao Xie, Tianen Chen, Jiahao Hu, Shijie Li, Sarun Juengpanic, Ziyi Lu, Bin Zhang, Kaitai Wang, Feng Xu, Jiliang Shen, Mingyu Chen
Abstract
Aim: To determine if PD-L1 can be used as a biomarker to predict the efficacy of anti-PD-1/PD-L1 inhibitors in hepatocellular carcinoma (HCC). Methods: Relevant studies from a specific search of the four databases from October 2014 to December 2022 were included in this meta-analysis. Results: Higher PD-L1 expression levels were associated with a higher objective response rate (ORR). Higher PD-L1 expression levels on tumor cells and tumor proportion score were associated with higher ORR. PD-L1 was capable of predicting the effectiveness of nivolumab. Dako 28-8 is a promising assay for HCC. Conclusion: PD-L1 is a predictive biomarker for ORR in HCC. Tumor proportion score and PD-L1 expression levels on tumor cells are potential scoring algorithms.